Biohaven Ltd., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Dina Ramadane from Bank of America Securities reiterated a Hold rating on the stock and has a $12.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dina Ramadane has given his Hold rating due to a combination of factors tied to Biohaven’s current fundamentals and pipeline outlook. The firm’s cash burn modestly exceeded expectations, leading her to trim the price objective from $14 to $12 per share and reallocate valuation toward the broader pipeline rather than neuropsychiatric uses of kv7, reflecting a more cautious stance on near-term financial and execution risk.
At the same time, she sees meaningful, albeit uncertain, upside from upcoming 2H26 catalysts, including pivotal data for opakalim in focal onset seizures and proof-of-concept obesity results for t‑alfa, as well as early but promising degrader programs in IgAN and Graves. Given the balance between these long-term opportunities and financing overhang, limited visibility on key readouts, and a valuation she views as fair, she expects the stock to remain range-bound and therefore maintains a Neutral, or Hold, recommendation.